...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cellular Physiology >Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin
【24h】

Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin

机译：身体质量指数和治疗结果转移性乳腺癌患者治疗

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Eribulin has shown survival advantage and manageable toxicity in heavily pre-treated metastatic breast cancer (mBC). We assessed whether body mass index (BMI) impacts treatment outcomes in 101 patients treated with eribulin at six Italian Oncologic Centers. BMI was addressed as a categorical variable (18.5-24.9 vs. at least 25). Clinical benefit rate (CBR) was assessed overall and in subgroups defined by BMI, line of therapy (LOT), and hormone receptor (HR) status. Analysis of CBR by LOT and HR status were further stratified by BMI. Survival curves were compared using the Kaplan-Meier method and log-rank test. Predictors of survival were tested in Cox models. Patients treated with eribulin as third line showed greater CBR when their BMI was in the lowest category (77.8 vs. 58.1%, P=0.03). Median progression free survival (PFS) and overall survival (OS) in normal and overweight patients were 4 (95% CI, 3-5) versus 3 (2.1-4) months, P=0.02 and 13 (11-15) versus 12 (6-18) months, P=0.96, respectively. Median PFS and OS in estrogen receptor (ER) positive and negative tumours were 4 (3-5) versus 3 (2-4) months, P=0.005 and 14 (10-18) versus 7 (4-10), P=0.02, respectively. In multivariate analyses, BMI impacted PFS at a nearly significant extent (P=0.05), while ER expression significantly affected PFS and OS (P=0.01 and 0.02, respectively). No relevant findings emerged concerning toxicity. We found evidence of greater efficacy of eribulin in leaner mBC patients, particularly if given as third line and in ER positive tumors. Further studies are warranted to confirm our findings. J. Cell. Physiol. 231: 986-991, 2016. (c) 2015 Wiley Periodicals, Inc.
机译：Eribulin表明生存优势在大量预处理的可控的毒性转移性乳腺癌(mBC)。身体质量指数(BMI)是否影响治疗结果患者在101年eribulin六名意大利肿瘤中心。作为分类变量(至少18.5 - -24.9 vs25）. 总体指数定义的子组,行治疗(很多),激素受体(人力资源)的地位。分析和人力资源状况进一步CBR的很多分层BMI。使用kaplan meier方法和生存率较。生存测试Cox模型的预测。患者eribulin第三行显示更大的CBR当他们的BMI最低类别(77.8和58.1%,P = 0.03)。无进展生存(PFS)和整体正常和超重患者的生存(OS)4 (95% CI, 3 - 5)和3(2.1 4)个月,P = 0.02和13(第11 - 15)和12(- 18)个月,分别P = 0.96。雌激素受体(ER)积极的和消极的肿瘤4(3 - 5)和3(2 - 4)个月,P = 0.005和14(10 - 18)与7(电场),P = 0.02,分别。几乎影响了PFS显著的程度(P = 0.05),而ER表达显著影响PFS和操作系统(P = 0.01和0.02,分别)。关于毒性。功效的eribulin精简mBC的病人,特别是作为第三行和ER积极的肿瘤。确认我们的发现。986 - 991年,2016年。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号